title: Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus.
abstract: Severe vaso-occlusive retinopathy is a relatively rare form of retinopathy in systemic lupus erythematosus (SLE). We report two patients with severe vaso-occlusive retinopathy in SLE who were treated with intravitreal bevacizumab (IVB). (Patient 1) A 35-year-old woman presented with left visual loss and was diagnosed with SLE after systemic evaluation. Despite systemic immunosuppressive therapy, retinal vascular obstruction progressed and neovascularization of the disk (NVD) developed. The patient was treated with IVB and pan retinal photocoagulation. The progression of vascular obstruction ceased and regressed. (Patient 2) A 24-year-old man with SLE presented with left visual loss. There was retinal vascular obstruction with macular edema in both eyes, and then the patient was treated with IVB. One month after injection, minimal capillary nonperfusion increased to 10 disk area, and 5 months later, neovascularization elsewhere (NVE) developed in the right eye. Six months after injection, vitreous hemorrhage with florid NVE and NVD developed in the left eye. In selected severe vaso-occlusive retinopathy in SLE patients, IVB may be an adjuvant option for treatment.
authors.affiliation: Department of Ophthalmology, Hanyang University College of Medicine, Seoul, Korea.
authors.forename: Won June
authors.initials: WJ
authors.lastname: Lee
authors.forename: Hee Yoon
authors.initials: HY
authors.lastname: Cho
authors.forename: Yoon Jung
authors.initials: YJ
authors.lastname: Lee
authors.forename: Byung Ro
authors.initials: BR
authors.lastname: Lee
authors.forename: Jae Pil
authors.initials: JP
authors.lastname: Shin
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015356:Retinal Artery Occlusion / Q000188:drug therapy* / Q000209:etiology; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012171:Retinal Vessels / Q000473:pathology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab